EEF2K Antibody

What is eEF2K and why is it significant in cancer research?

eEF2K is a calcium/calmodulin-activated member of the α-kinase family that regulates mRNA translation by phosphorylating eEF2, which mediates the movement of polypeptidyl-tRNAs during protein synthesis. The significance of eEF2K in cancer research stems from its overexpression in various malignancies including pancreatic, brain, breast cancer, and melanoma . Research has demonstrated that eEF2K promotes:

• Cell survival under nutrient deprivation, hypoxia, and therapeutic stress

• Cancer cell proliferation through regulation of aerobic glycolysis

• Autophagy modulation, affecting drug resistance mechanisms

• EMT, angiogenesis, tumor cell migration and invasion

• PD-L1 stabilization, influencing immune checkpoint therapy responses

Importantly, recent studies have found that eEF2K may serve as a biomarker for predicting therapeutic response to anti-PD-1 therapy, particularly in melanoma .

What applications can eEF2K antibodies be used for in experimental research?

Based on commercial antibody specifications, eEF2K antibodies can be used in multiple applications:

For optimal results, antibody titration is recommended in each testing system, as sensitivity may be sample-dependent .

How do I select the appropriate eEF2K antibody for my experiment?

Selection should be based on:

• Reactivity: Confirm species cross-reactivity (e.g., human, rat, monkey) matches your experimental model

• Epitope specificity: Choose between total eEF2K antibodies or phospho-specific antibodies targeting particular sites (e.g., p-eEF2K at Ser366)

• Application validation: Verify the antibody has been validated for your specific application

• Positive controls: Check if known positive control samples are available

• Knockout validation: Some antibodies have been validated in knockout experiments, providing higher confidence in specificity

For phosphorylation-dependent studies, specifically validated phospho-antibodies (like p-eEF2K Antibody H-2 that detects Ser366 phosphorylation) are essential for accurate assessment of kinase regulation states .

How can I effectively use eEF2K antibodies for studying protein-protein interactions?

For investigating eEF2K interactions with binding partners such as GSK3β or STAT3:

• Co-immunoprecipitation (Co-IP) protocol:

  • Lyse cells in non-denaturing buffer (typically containing 1% NP-40 or Triton X-100)

  • Pre-clear lysate with protein A/G beads

  • Incubate with eEF2K antibody (0.5-4.0 μg per 1-3 mg protein)

  • Capture antibody-protein complexes with protein A/G beads

  • Wash extensively (4-5 times) to remove non-specific binding

  • Elute and analyze by western blotting for interacting proteins

• Proximity ligation assay (PLA) for visualizing in situ interactions:

  • Fix cells and permeabilize with 0.1% Triton X-100

  • Block with appropriate blocking buffer

  • Incubate with primary antibodies against eEF2K and potential interactor

  • Follow manufacturer's protocol for PLA probe incubation and signal amplification

  • Image using fluorescence microscopy

Research has revealed that eEF2K directly binds to and inactivates GSK3β by phosphorylating it at serine 9, leading to PD-L1 protein stabilization . These methodologies can help validate similar interactions.

What are the optimal conditions for detecting phosphorylated eEF2K in various cancer cell models?

Phosphorylated eEF2K detection requires specific considerations:

• Sample preparation:

  • Rapidly harvest cells in ice-cold phosphate-preserving lysis buffer

  • Include phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate)

  • Maintain cold temperature throughout processing

• Western blot optimization:

  • Use phospho-specific antibodies like those targeting p-eEF2K Ser366

  • Block with 3-5% BSA rather than milk (phospho-epitopes can bind to casein)

  • Include phosphatase inhibitors in all wash buffers

  • Consider using PVDF membranes which may provide better signal for phosphoproteins

• Model-specific considerations:

  • For melanoma: MDA-MB-231 and HCC1806 cell lines show differential eEF2K expression levels

  • For TNBC models: Verify baseline eEF2K expression levels as they correlate with experimental response

What controls should be included when studying eEF2K antibody specificity and experimental reliability?

Western blot analysis comparing normal and eEF2K knockout HeLa cells has demonstrated the specificity of certain commercial antibodies, showing complete absence of signal in knockout samples . Such validation is crucial before proceeding with complex experiments.

How should I design experiments to study the relationship between eEF2K and PD-L1 expression in cancer models?

Based on recent findings about eEF2K's role in PD-L1 stabilization , consider this experimental design:

• Cell model selection:

  • Choose cell lines with varying baseline eEF2K expression (e.g., melanoma or TNBC lines)

  • Include both high and low PD-L1 expressing models

• Genetic manipulation approaches:

  • Generate stable eEF2K knockdown lines using shRNA (at least two different constructs)

  • Create eEF2K overexpression models

  • Include non-target shRNA controls

• Drug intervention studies:

  • Test eEF2K inhibitors (e.g., NH125) at various concentrations

  • Examine combination effects with anti-PD-1 antibodies

• Readout measurements:

  • Assess PD-L1 protein levels via western blotting

  • Measure PD-L1 half-life using cycloheximide chase assays

  • Evaluate GSK3β phosphorylation at Ser9

  • Monitor T cell activity markers (CD8, GZMB) in co-culture systems

• In vivo validation:

  • Establish mouse xenograft models

  • Compare eEF2K knockdown vs. control tumors

  • Analyze tumor infiltrating lymphocytes

This comprehensive approach has revealed that eEF2K directly binds to and inactivates GSK3β by phosphorylating it at Ser9, leading to PD-L1 stabilization and immune evasion .

What are common issues with eEF2K antibody staining in immunofluorescence and how can they be resolved?

When optimizing protocols, A-549 cells have been successfully used for immunofluorescence detection of eEF2K as demonstrated in validation studies . Starting with a cell line known to express eEF2K can help establish working conditions.

How do I interpret conflicting results when eEF2K expression correlates with both better and worse cancer outcomes in different contexts?

This apparent contradiction can be explained by understanding context-dependent functions:

• Positive correlation with anti-PD-1 response:

  • Higher eEF2K expression correlates with better therapeutic response and longer survival in melanoma patients receiving anti-PD-1 therapy

  • Mechanistically, eEF2K promotes PD-L1 expression, creating a more immunogenic tumor

  • This makes tumors more responsive to checkpoint inhibition

• Negative effects on tumor progression:

  • EEF2K silencing attenuates malignant phenotypes including proliferation, migration, and invasion

  • EEF2K promotes cancer through mechanisms like the p-STAT3/SPP1 pathway

  • Acts as a survival factor under stress conditions

• Reconciling conflicting data:

  • Consider treatment context (immune checkpoint therapy vs. other approaches)

  • Evaluate cancer type specificity (melanoma vs. TNBC)

  • Assess baseline immune infiltration in the tumor microenvironment

  • Consider combination therapy effects (eEF2K inhibition + anti-PD-1)

These findings suggest that while eEF2K may promote tumor growth through multiple pathways, its enhancement of PD-L1 expression paradoxically makes tumors more responsive to immunotherapy targeting the PD-1/PD-L1 axis .

How can eEF2K antibodies be utilized in proteomics approaches to identify novel downstream targets?

Several proteomics strategies can identify eEF2K targets:

• SILAC combined with BONCAT approach:

  • Stable isotope labeling with amino acids in cell culture (SILAC) enables quantification of changes in protein synthesis

  • Bio-orthogonal non-canonical amino acid tagging (BONCAT) allows selective isolation of newly synthesized proteins

  • This combined approach revealed that synthesis of microtubule-related proteins is particularly sensitive to eEF2K inhibition

  • Implementation requires metabolic labeling of cells with heavy isotopes and/or non-canonical amino acids

• Immunoprecipitation-mass spectrometry (IP-MS):

  • Use eEF2K antibodies to pull down eEF2K and associated proteins

  • Analyze by mass spectrometry to identify binding partners

  • This approach identified GSK3β as a direct binding partner and substrate of eEF2K

• Phosphoproteomics:

  • Compare phosphoproteomes of control vs. eEF2K-inhibited or knockout cells

  • Identify differentially phosphorylated proteins as potential downstream effectors

  • Validate findings using phospho-specific antibodies

These methodologies require careful experimental design considering the complexity and expense of mass spectrometric analyses .

What is the potential for targeting eEF2K in combination cancer therapies based on recent research?

Recent findings reveal several promising combination strategies:

• eEF2K inhibition + immunotherapy:

  • eEF2K inhibitor NH125 or eEF2K knockdown enhanced the efficacy of PD-1 mAb therapy in melanoma models

  • This creates a potential combination therapeutic strategy for patients receiving immune checkpoint blockade

• eEF2K degraders + chemotherapy:

  • Novel small-molecule eEF2K degrader compound C1 shows synergistic effects when combined with paclitaxel against TNBC both in vitro and in vivo

  • Acts as a molecular glue enhancing interaction between eEF2K and ubiquitin E3 ligase βTRCP

• eEF2K silencing + BET inhibitors:

  • EEF2K silencing combined with BET inhibitor treatment further inhibits cell proliferation and promotes apoptosis in melanoma

  • Suggests potential for epigenetic therapy combinations

• Biomarker-guided therapy selection:

  • High eEF2K expression correlates with better response to anti-PD-1 therapy in melanoma

  • Could be used as a predictive biomarker for immunotherapy selection

The efficacy of these combinations appears to be dependent on baseline eEF2K expression levels, as demonstrated in TNBC cell lines where anti-proliferative effects of compound C1 correlated with eEF2K expression .